|Home | About | Journals | Submit | Contact Us | Français|
The successful restoration of visual function with recombinant adeno-associated virus (rAAV)-mediated gene replacement therapy in animals and humans with an inherited disease of the retinal pigment epithelium has ushered in a new era of retinal therapeutics. For many retinal disorders, however, targeting of therapeutic vectors to mutant rods and/or cones will be required. In this study, the primary cone photoreceptor disorder achromatopsia served as the ideal translational model to develop gene therapy directed to cone photoreceptors. We demonstrate that rAAV-mediated gene replacement therapy with different forms of the human red cone opsin promoter led to the restoration of cone function and day vision in two canine models of CNGB3 achromatopsia, a neuronal channelopathy that is the most common form of achromatopsia in man. The robustness and stability of the observed treatment effect was mutation independent, but promoter and age dependent. Subretinal administration of rAAV5–hCNGB3 with a long version of the red cone opsin promoter in younger animals led to a stable therapeutic effect for at least 33 months. Our results hold promise for future clinical trials of cone-directed gene therapy in achromatopsia and other cone-specific disorders.
Most vision-impairing disorders in humans result from genetic defects, and, to date, mutations have been identified in ~150 genes out of ~200 mapped retinal disease loci (RetNet: http://www.sph.uth.tmc.edu/RetNet/). This wealth of genetic information has provided fundamental understanding of the multiple and specialized roles played by photoreceptors and the retinal pigment epithelium (RPE) in the visual process, and how mutations in these genes result in disease. Together with the development of gene transfer technologies, it is now possible to realistically consider the use of gene therapy to treat these previously untreatable disorders. A new era of retinal therapeutics has been started by recent studies, showing that treatment of animal models with gene therapy successfully restored visual function (1–3). These results have been translated to the clinic and been shown to be safe and successful for a human retinal degeneration caused by RPE65 mutations (4–11).
However, this example of an RPE disease is rare and complex in that loss of visual function and eventual photoreceptor degeneration is secondary to a biochemical blockade of the RPE visual cycle. While it has been an ideal test platform for the first clinical gene therapy trial for blindness in man, RPE65 disease is not representative of the diversity of more common retinal disorders that could be considered for gene therapy where the target cells are the rods and/or cones. For these, successful targeting of therapeutic vectors to mutant photoreceptors to restore function and preserve structure will be required, and achieving this initially in experimental animals is necessary for eventual application to humans.
Congenital achromatopsia, also called rod monochromacy or total congenital color blindness, is a rare autosomal recessive disorder with an estimated prevalence of about 1 in 30 000–50 000 (12–15). Because it primarily affects cones, it serves as the ideal translational model to develop gene therapies directed to photoreceptors. Even though cones are numerically small, ~5% of the photoreceptors in man (16), they are essential for color vision, central visual acuity and most daily visual activities, functions that are severely impaired or absent in affected patients. Thus far, four genes have been identified to cause achromatopsia in human patients, all of them encoding principal components of the cone phototransduction cascade: the alpha subunit of cone transducin [GNAT2 (17–19)], the catalytic alpha' subunit of the cone phosphodiesterase (PDE6C) (20,21) and the alpha [CNGA3 (22–24)] and beta [CNGB3 (25–28)] subunits of the cone cyclic nucleotide-gated (CNG) channel located in the plasma membrane of the cone outer segment. The majority of human achromatopsia (~70–92%) are considered channelopathies as they are caused by mutations in either CNGA3 or CNGB3 (29–32). The CNGB3 gene appears to be the most prevalent causal gene for achromatopsia in patients of Northern European descent, with reported prevalence between 50 and 87% (29,32). However, it is suspected that CNGA3 mutations are more prevalent among patients from the Middle East (33).
Based on the very high prevalence of the CNGB3 mutations in autosomal recessive achromatopsia (29,32), our identification of two independent canine models with distinct CNGB3 mutations has provided us with a unique, physiologically relevant system in which to assess potential gene therapy strategies designed to restore visual function (34). These models result from either a missense mutation in exon 6 (CNGB3m/m) or a genomic deletion of the entire CNGB3 gene (CNGB3−/−, ‘null mutation’) (34). The canine disease caused by the null mutation has been characterized, and shares the same clinical phenotype as human patients (35–38). The classic achromatopsia phenotype develops between 8 and 12 weeks of age, soon after retinal differentiation is completed (35–38); however, other than the salient functional and structural abnormalities in affected cones, the retina remains normal throughout life (36,38).
Here we report the successful restoration of cone function and associated photopic vision in both canine achromatopsia models by gene replacement therapy. We used recombinant adeno-associated virus serotype 5 (rAAV5) with different forms of the human red cone opsin promoter. The robustness and stability of the observed treatment effect was mutation independent, but promoter and age dependent. These results hold promise for future clinical trials in human patients with CNGB3-achromatopsia.
In contrast to human and nonhuman primates that have separate populations of red, green and blue cones, dogs are functional dichromats, with cone populations having combined red/green and blue pigments (39). These are termed long/medium-wavelength-absorbing cones (L/M-cones) and short-wavelength-absorbing cones (S-cones), and have maximal sensitivities of 555 and 429–435 nm, respectively (39,40). The number, distribution and ratios of L/M- and S-cones in the normal canine retina have recently been reported, and L/M-cones outnumber S-cones by a ratio of 8:1 in the areas selected for therapy [see Materials and Methods (41)].
Dogs with either the CNGB3−/− or CNGB3m/m mutation are blind in bright light after ~8 weeks of age, a time point when vision can be reproducibly evaluated (35–38,42). At this age, cone-mediated function is absent, but rod responses are normal (Fig. 1). Despite the loss of cone function, both L/M- and S-cones are present, and express markers characteristic of their differentiated state (Fig. 2). Cone arrestin is expressed in both L/M- and S-cones, but expression in the outer segments appears to be more intense in the former (Fig. 2). Although there has been quantification of the rate of cone loss in canine CNGB3-achromatopsia with time (unpublished data), we find that the process is slow with many cones still present in older affected dogs (Supplementary Material, Fig. S1). Thus the time window for cone-targeted gene replacement therapy deserves examination.
In an effort to direct treatment to cones, we first asked whether mutant cones could be transduced with vectors conveying reporter constructs and promoters that are derived from L/M-cones. We previously reported the effectiveness and specificity of rAAV5 and different versions of the human red cone opsin promoter to direct cell class-specific GFP expression to L/M-cones in normal and diseased (primary, early rod degeneration caused by PDE6B mutation) canine retina (43). In preparation for rAAV5-mediated gene replacement therapy in CNGB3-achromatopsia, we confirmed that the longer (PR2.1) and shorter (3LCR-PR0.5) variants of the human red cone opsin promoter were also able to target L/M-cones in mutant canine retinas (Table 1). We found that gene expression could be targeted specifically to nonfunctional L/M-cones in the CNGB3-mutant retina, and that the robustness of expression was promoter dependent. While the PR2.1 led to strong GFP expression that could easily be visualized by direct GFP fluorescence, expression with the shorter 3LCR-PR0.5 promoter was weaker, and required immunohistochemical enhancement to visualize the transduced cones (Fig. 3). We also verified that the transfection of cones only occurred in the area of the subretinal bleb, and that GFP-gene expression levels diminished sharply beyond the bleb margins (Fig. 3). Both PR2.1 and 3LCR-PR0.5 promoters were subsequently used for rAAV5-mediated gene replacement therapies. The shortest version of the human red cone opsin promoter PR0.5 was not evaluated with the GFP reporter gene in CNGB3-mutant retinas, but was tested in the therapeutic studies. We did not attempt to use the human blue cone opsin promoter because we previously found that expression was promiscuous, with GFP present in few L/M-cones, some rods and RPE, but not in S-cones (43).
A single subretinal injection of rAAV5 vector containing the human CNGB3 (hCNGB3) transgene restored cone function in CNGB3-mutant dogs as measured by cone flicker electroretinograms [ERGs (Fig. 1)]. In dogs maintained for long-term follow-up, the rescued cone function was sustained for well over 1 year with the longest period of observation being ~2.5 years (130 weeks), suggesting that the correction is stable and probably permanent (Table 1 and Fig. 4). This successful treatment outcome was mutation independent, but promoter and age dependent (Table 2), and there was no difference in treatment outcomes between the CNGB3m/m and the CNGB3−/− animals.
Efficient and sustained cone function rescue could not be achieved with vectors containing the two shorter promoters, PR0.5 and 3LCR-PR0.5. Despite undetectable GFP expression in canine cones with the shortest human red cone opsin promoter PR0.5 (43), it resulted in transient restoration of cone function in one of two injected eyes (Table 2). Using the more robust 3LCR-PR0.5 promoter (43), two of seven injected eyes showed transient restoration of cone function (Table 2). In the eyes responding to the injections with either of the shorter promoters, recordable ERG cone function was present at 3 weeks after therapy, but was lost by 13 weeks. In contrast, the longest promoter, PR2.1, provided robust and stable rescue of cone function in 12 of 17 eyes (Table 2); once rescue of cone function was achieved, it was sustained.
In addition to promoter effectiveness, we studied the age dependence on functional cone rescue. Even though many cones are still present in affected older dogs several years of age (Supplementary Material, Fig. S1), we observed that only one of three eyes of dogs over 54 weeks of age showed a clear restoration of cone function when treated with vector having the PR2.1 promoter. In contrast, 11 out of 14 eyes responded when treatment was done in eyes less than 28 weeks of age (Table 2). Similar outcomes were observed with the two other shorter human red cone opsin promoters although the number of animals evaluated in each group was smaller.
In addition to not having found rescue of function following the application of GFP vectors, we ruled out a sham-treatment effect by injecting 10 eyes of 8 dogs (5 CNGB3−/− and 3 CNGB3m/m) between 4 and 76 weeks of age subretinally with comparable volumes of the vector excipient balanced salt solution (BSS, Alcon Laboratories, Inc., Fort Worth, TX, USA). Cone function was not restored in any of these animals (data not shown), an indication that return of cone function was entirely dependent on the presence of the hCNGB3 transgene in the vector.
In addition to the electrophysiologic documentation of cone function recovery, qualitative and quantitative vision testing was performed on selected dogs following gene therapy. Initially vision under bright-light conditions was assessed subjectively by observing the dogs maneuver around randomly placed obstacles in a confined area. Untreated dogs showed clear signs of day-blindness, including hypermetric gate, disorientation and collision with obstacles, while treated dogs were sighted (Supplementary Material, Movie S1). All animals exhibited no visual deficits in a dim-light environment.
To assess visual function in a more quantifiable and objective manner, seven affected dogs, six treated with PR2.1-hCNGB3 and one with PR0.5-hCNGB3, had their visual function tested objectively under scotopic and photopic conditions in an obstacle avoidance course. Objective identification of achromatopsia was based on transit time, a quantitative response variable (42). There was a significant increase in mean transit times of achromatopsia-affected dogs in ambient light intensities of ≥25 lux, while the mean transit times of normal control dogs were not affected by any ambient light conditions (Fig. 5). In contrast, following gene therapy in affected dogs, transit times under photopic conditions approached normal values, but were still slower. This remaining difference between normal and treated affected dogs is expected, given that normal dogs function binocularly in the obstacle course, whereas the treated dogs received the vector injection in only one eye. Additionally, only ~30% of the retina was treated. Given these differences, the behavioral similarities between normal and treated dogs are remarkable. Performance in the obstacle course is illustrated in Supplementary Material, Movie S2.
To more fully assess rescue of the cone phenotype, the expression and localization of cone alpha transducin GNAT2 and CNGA3 proteins was evaluated by immunohistochemistry. In the normal retina, both GNAT2 and CNGA3 were found in the cone outer segments. In contrast, the nonfunctional cones in the CNGB3−/− and CNGB3m/m retinas did not have either GNAT2 or CNGA3 in the outer segments (Fig. 6), but western blot analysis demonstrated that the CNGA3 protein was present in the retina (Fig. 6). This was previously reported for other transducin subunits in the canine CNGB3−/− retina (44,45). At all time points evaluated, the examination of successfully treated retinal regions showed restoration of protein localization to cone outer segments for both GNAT2 and CNGA3 associated with rescued function (Fig. 6). This was limited to the vector-treated area and not visible in untreated regions (data not shown). We interpret these findings to indicate that successful restoration of cone function was accompanied by relocation of CNG channel components and transducin, both elements of the phototransduction cascade, to their proper cone outer segment compartment.
All the retinas analyzed at various times following subretinal rAAV5-hCNGB3 injection showed expression of the hCNGB3 transgene as measured by quantitative real-time PCR [qRT-PCR (Fig. 7)]. The robustness of transgene expression with the PR2.1 promoter confirmed our previous findings using reporter GFP expression with this promoter (43). For comparison we also measured mRNA levels of canine CNGB3 (cCNGB3), S-opsin, L/M-opsin and rod opsin relative to the 18S rRNA endogenous control. In treated eyes that did not show recovery of cone function, the hCNGB3-transgene expression was lower, by ~3.6–150-fold when compared with successfully treated eyes, but clearly still detectable (Fig. 7). This means that hCNGB3 transgene expression must exceed a threshold level to be sufficient to restore the cone function. As expected, expression of cCNGB3 mRNA was not present in null mutant dogs, but was comparable with wild-type animals in the missense mutant dogs (Fig. 7). When we compared the detectable retinal hCNGB3 transgene expression levels with the cone flicker ERG amplitudes measured before tissue collection, we found a highly significant nonparametric Spearman rank correlation of 0.85 (P < 0.0001); that is, the cone ERG flicker amplitude increased with higher hCNGB3 transgene expression (Fig. 7).
We report that gene replacement therapy restores retinal cone function in two canine models of CNGB3 achromatopsia, a neuronal channelopathy. Restored cone function was documented by cone-specific ERG and recovery of day vision. As mutations in CNGB3 are the most common cause of achromatopsia in humans, our results hold promise for future clinical trials. We also showed that the restoration of cone function is mutation independent, but promoter and age dependent. Using vectors with the PR2.1 promoter, phenotypic correction is stable and probably permanent.
Results with vectored GFP reporter gene in mutant retinas confirmed that cones are present despite total lack of function after 8 weeks of age, and that gene expression can selectively be targeted to them. We previously showed the specificity and robustness of some human red cone opsin promoters, the shorter 3LCR-PR0.5 and the more robust longer PR2.1, to target GFP reporter gene expression to normal canine cones (43). The same two promoters allowed us to also target the nonfunctional cones in the two strains of CNGB3-mutant dogs with the same robustness as in normals. We also confirmed that transgene expression is limited to the area of the subretinal bleb, and then gradually fades beyond the treatment borders (43,46,47). In contrast to the high efficiency and specificity obtained with the human red cone opsin promoters, we have not been able to target canine S-cones with the currently available human S-cone promoter (43). Work in several species has showed that S-cones can be targeted, but with low specificity (48–51). Even though optimizing targeting to all classes of cones would be desirable from a therapeutic perspective, S-cones represent the minority in both dogs [9–12% of the total cone population (41)], and most other mammalian species including human and nonhuman primates (52,53). Thus significant clinical improvement of quality of life and vision can be expected even with restoration of only M- and L-cone functions.
The robustness of GFP expression observed with each promoter matched the outcome of rescued cone function, i.e. the highest success rate with the longest lasting treatment effect was achieved with the longest promoter, PR2.1. The shorter 3LCR-PR0.5 promoter also resulted in recordable restored cone function, but with a much smaller success rate and only transiently. The use of the shortest promoter, PR0.5, resulted in transient restoration of cone function even though we could not detect any expression of GFP reporter gene in normal dogs (43). We do not have a clear explanation for the transient treatment effect observed with the shorter promoters other than postulating an initial peak in hCNGB3 transgene expression that then decreased below a therapeutic threshold. This would be reflected in longitudinal changes in expression during the first few weeks after subretinal injection, but such a study has not been done yet. A trophic factor response to the insult of the subretinal injection is not likely as we have not found such an effect in the GFP-vector and BSS injected eyes.
The level of hCNGB3 transgene expression significantly differed between retinas that were successfully treated with the PR2.1 promoter and retinas that only transiently responded with the 3LCR-PR0.5 promoter. The importance of transgene expression levels is further supported by its significant correlation with cone flicker ERG amplitudes. What remains unclear is the minimum level needed to restore function. Several animals that failed to respond to the treatment with the longer PR2.1 promoter still showed levels of expression close to those with rescued cone function. In order to gain clarity about some of these questions, transgene expression should be monitored over time to determine its kinetics and to compare it to the timeline of rescued cone function and recovery of day vision. Because none of the therapeutic failures could be explained solely by lack of transgene expression, other factors may also determine the restoration of cone function, e.g. the synthesis of CNGB3 protein in sufficient quantities and the proper assembly of the CNGA3 and CNGB3 protein subunits into a functional tetrameric outer segment channel (54). As well, there was no observable retinal damage that could have explained a failed therapeutic effect despite detectable hCNGB3 transgene expression.
In addition to promoter effects, we also observed a reproducible reduction in the cone therapy success rate in dogs treated at 54 weeks of age or older. The underlying molecular mechanism for this phenomenon remains to be determined, particularly in view of the fact that many cones that appear structurally normal are still present in older animals. We have not observed such an age-effect in our previous work on rAAV-mediated gene therapy in dogs with Leber Congenital Amaurosis caused by RPE65-mutation (RPE65-LCA) (55). One possibility is that it may result from the greater complexity of interacting phototransduction elements in photoreceptors, either rods or cones, in comparison to those of the retinoid cycle in the RPE. This might suggest that a return to ‘normal’ following gene replacement therapy in photoreceptors requires more protein reorganization than it does for comparable therapy in the RPE. This issue may have a potential impact on the age of patients initially selected for an achromatopsia gene therapy clinical trial.
We have not observed a detrimental effect of potential hCNGB3 transgene overexpression, which probably occurred with the PR2.1 promoter, on the cone photoreceptors, particularly in missense mutant dogs. One can imagine that too many CNG channels on the cone outer segment membrane may negatively affect the cones. However, CNG channels are heterotetramers that are composed of homologous alpha and beta subunits (CNGA3 and CNGB3 in cones) (56,57), and it is possible that the number of CNG channels in the cone outer segment membrane is determined primarily by the expression levels of CNGA3 rather than CNGB3.
Our results represent the second successful cone-directed gene replacement therapy in achromatopsia animal models; the first being rAAV-mediated gene therapy of the GNAT2cpfl3 mutant mouse (58). The value of our results lies in the fact that the achromatopsia dogs represent the only natural large animal model of CNGB3-achromatopsia, the most common form of the disease in man (29,32). Furthermore, the canine disease is unlike some of the naturally occurring or experimental mouse achromatopsia models which are characterized by early and rapid cone cell loss (59,60). The CNGB3 mutant dog retina shows normal development and preservation of cones, and degeneration and loss occur slowly, thus increasing the therapeutic time window.
We documented the successful gene therapy in the CNGB3-mutant dogs by the restoration of both the cone ERG and by objective measure of day vision behavior. The behavioral results suggest that inner retinal cells and central visual pathways were able to usefully process the input from the recovered cones, at least within the ages treated. The cortical effects of the functional deficit, however, are not clear at present, and are important areas for further studies of translational significance. That visual cortical plasticity occurs in response to changes in peripheral inputs has been described in recent work in the mouse and squirrel monkey where inner retinal cells and central visual pathways are able to adjust an additional cone cell class (61,62). Achromatopsia studies in man have shown a large-scale reorganization of the visual cortex in which the cortical region that normally responds to signals from the all-cone foveola, and is inactive in normal subjects under rod viewing conditions, becomes highly responsive to rod-initiated signals (63). One possibility is that restoration of central cone function in such patients would result in remapping of the visual cortex, although such studies would need to be carried out only after confirming cone ERG restoration upon treatment. Even though dogs lack a foveo-macular region, they are an excellent model to examine cortical plasticity upon vector treatment as shown by the functional cortical imaging methods being currently developed (55) using ‘silent substitution methods’ that are able to separate rod versus cone, and S-cone versus L/M-cone cortical responses (64).
In conclusion, robust, long-term rescue of cone function was achieved in 2 canine models of CNGB3-achromatopsia. As mutations in CNGB3 are the most common cause of human achromatopsia, studies on a corresponding natural disease in dogs offer unique opportunities for proof-of-principle experiments examining cone-directed gene therapy for eventual translation to patients. Because cones are also compromised in many other retinal diseases, e.g. cone dystrophies (21,22), or cone-rod dystrophies (65,66), and secondarily in many forms of age-related macular degeneration (AMD) (67,68) and retinitis pigmentosa (69–71), results reported here offer a promise for future cone-directed gene therapy in humans.
A total of 33 achromatopsia-affected dogs were studied, both males and females, between 3 and 81 weeks of age. These had either a genomic deletion (CNGB3−/−; n = 24) or a missense mutation (CNGB3m/m; n = 9) of the CNGB3 gene (Table 1) (34). The animals were part of a research colony maintained at the Retinal Disease Studies Facility (Kennett Square, PA, USA) and supported by the National Eye Institute, NIH (EY-06855), and a Foundation Fighting Blindness Center grant. For terminal procedures, the dogs were euthanatized with an overdose of sodium pentobarbital, and the eyes enucleated for molecular and protein studies and immunohistochemistry. All procedures in this study were approved by the University of Pennsylvania IACUC, and were done in accordance with the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research.
Recombinant adeno-associated virus vectors of serotype 5 (rAAV5) were used. The vector constructs with the green fluorescent protein (GFP) reporter gene have recently been described (43). The CNGB3 therapeutic vectors were constructed similarly with the hCNGB3 cDNA replacing the GFP coding sequence. Promoter constructs were based on the same red-cone opsin promoter derived from the pR2.1-LacZ plasmid containing bases spanning -4564 to -3009 and -496 to 0 of the human red cone pigment gene driving LacZ (49). Briefly, the vector plasmid pTR-PR2.1-Gnat2 was digested with NotI to release the murine Gnat2 gene, and the NotI linearized pTR-PR2.1 backbone was isolated. A plasmid containing the human CNGB3 gene (2430 bp) was use as a template for a PCR reaction with primers (forward 5′-TTTGCGGCCGCATGTTTAAATCGCTGACAAAAGTCA-3′ and reverse 5′-TTTGCGGCCGCTTATTGCTTAGCCTTTTCTTTGACT-3′) to introduce NotI sites 5′ and 3′ of the ATG start and TAA stop codons, respectively, of CNGB3. The CNGB3 PCR product was sub-cloned into a pCR-Blunt vector, digested with NotI, isolated, and cloned into the pTR-PR2.1 backbone to create the vector plasmid pTR-PR2.1-hCNGB3. The vector plasmid also contains an SV40 Poly-A tail located 3′ of the stop codon. The rAAV constructs for PR0.5 and 3LCR-PR0.5 driving hCNGB3 were created in a similar manner. Briefly, only the ‘core’ −496 to 0 promoter sequence was used for PR0.5, and three copies of the 37 bp locus control region fused to the upstream sequence of the core promoter was used for 3LCR-PR0.5. SURE cells (Stratagene, La Jolla, CA) were used to propagate all rAAV constructs. The final sequence for the hCNGB3 gene used in our study differed from the published sequence in two places: (i) at +540 were an A to G at the third position in the codon resulted in a silent mutation (Pro to Pro) and (ii) at +892 where an A to C at the first position in the codon resulted in a missense mutation (Thr to Pro), a known polymorphism in the gene (28). Production and purification of rAAV5 was carried out by procedures similar to those previously described (72,73). Quantitative real-time PCR (qRT-PCR) was used to determine titer, and the final rAAV5 aliquots in BSS (Alcon Laboratories, Inc.) with 0.014% Tween 20 were stored at −80°C.
Subretinal administration of vector containing either a reporter or therapeutic gene was performed in 25 dogs (CNGB3−/−, n = 19; CNGB3m/m, n = 6) ranging in age from 3 to 81 weeks of age with a RetinaJect™ subretinal injector (SurModics, Inc., Eden Prairie, MN, USA) through a transvitreal approach under general anesthesia using methods previously described (43,74). The majority of dogs had unilateral injections, and the fellow eye served as control. In all cases, the area treated was in the tapetal zone superior to the optic disc, a region with very high cone density (41). Because eye size changes dramatically with age, and there are limits to the volume that can be delivered to the subretinal space, vector volumes were chosen so that most of this region was covered; these ranged between 60 and 190 µl. Vector concentrations varied somewhat in different production lots, but most were in the range of 1012 vector genomes (vg)/ml. In order to rule out a sham-treatment effect by the subretinal injection alone, 10 eyes of 8 dogs (5 CNGB3−/− and 3 CNGB3m/m) aged between 4 and 76 weeks were injected with comparable volumes of BSS. Immediately following surgery, the retinal location and the extent of the subretinal blebs were documented by fundus drawings for reference in the morphologic studies. Details of the injections and experimental procedures performed in animals receiving either the therapeutic or reporter gene constructs are summarized in Table 1.
Postoperative management included a combination of subconjunctival steroids, topical antibiotic-steroids and mydriatics, and short-term systemic steroids and antibiotics as described previously (43,74). Using this protocol, the uveitis induced by the surgical trauma remained mild, and no signs of ocular pain or periocular swelling were noticed. Following surgery, the dogs were monitored by routine ophthalmic examination with binocular indirect ophthalmoscopy and slitlamp biomicroscopy. Flattening of the subretinal bleb occurred within 24–36 h. In general, the surgical procedure and vectors were well tolerated. Expected side effects were limited to mild anterior and posterior uveitis immediately after subretinal injection that was easily controlled with the routine medical management (43,74). In 3 of the 17 eyes injected with the rAAV5-PR2.1-hCNGB3 vector, a multifocal chorioretinitis developed between 3 and 5 weeks postinjection. This abnormality developed only at higher vector concentrations was easily controlled with systemic steroid treatment and no longer occurred when vector doses were lowered. Long-term we found variable degrees of retinal scarring in the region of the retinotomy site; these changes have been documented before (75). However, four animals injected with a particular rAAV5 vector lot developed severe, sterile, endophthalmitis within 12–24 h subretinal injection due to endotoxin contamination of the vector preparation. These animals were not included in this report, and the problem has been resolved by additional purification steps.
Standard Ganzfeld scotopic (dark-adapted) and photopic (light-adapted) ERGs were obtained from anesthetized dogs, using a modified Ganzfeld dome fitted with the LED light stimuli transferred from a ColorDome stimulator (Diagnosys LLC, Lowell, MA, USA). The ERGs were recorded with custom-built Burian-Allen bipolar contact lens electrodes (Hansen Labs, Coralville, IA, USA), commercially available platinum subdermal needle electrodes (Grass Safelead Needle electrodes; Grass Technologies, Astro-Med, Inc., West Warwick, RI, USA) and the Espion E2 computer-based system (Diagnosys LLC). Following premedication (acepromazine maleate, 0.5 mg/kg SQ; atropine sulfate, 0.03 mg/kg SQ) and intravenous thiobarbiturate induction (thiopental sodium, 25 mg/kg), the dogs were maintained under isoflurane inhalation anesthesia for the ERG recordings. The procedures for electroretinography setup were standard and have been reported previously (76,77). Rod and mixed cone-rod mediated responses were recorded after 20 min of dark-adaptation with scotopic single white flash stimuli of increasing intensities (from 0.000577 to 10.26 cd s/m2). Following 10 min of light-adaptation to a background illumination of 34.26 cd/m2, 1 Hz single flash (from 0.00577 to 10.26 cd s/m2) and 29.41 Hz flicker (from 0.00577 to 5.77 cd s/m2) cone-mediated signals were recorded. Except for the brighter scotopic light stimuli (≥0.577 cd s/m2), multiple responses were averaged.
To complement the retinal functional studies, we developed an obstacle course that provides an objective assessment of visual performance in dogs under variable scotopic and photopic conditions. Details of the apparatus and testing method have been described previously (42). The testing is comparable with that used in human patients in one of the RPE65 clinical trials [PAMELA—Pedestrian Accessibility and Movement Environment Laboratory (7)]. With this testing modality, we can reliably and reproducibly distinguish affected achromatopsia dogs from normal dogs because of their significantly longer transit time through the course at light intensities ≥25 lux (42). For every dog, the averaged transit time from three trials at each of the four illuminance levels was used for data analysis. Comparisons of mean transit times between groups were conducted using a generalized linear model, which adjusts the correlation from repeated measures at various illuminance levels in the same dog.
Following enucleation, the eyes were fixed for 3 h in 4% paraformaldehyde in 0.1 m phosphate-buffered saline at 4°C, and processed for embedding in optimal cutting temperature medium as described previously (78). Using the fundus drawings made immediately following subretinal injection and in the clinical examinations done posttreatment, the globes were oriented prior to trimming, so that treated and untreated regions of the eye were included for evaluation in the same retinal sections. Ten micrometer cryosections were cut and examined for intrinsic GFP fluorescence, immunohistochemistry or after H&E staining to examine retinal morphology and assess any adverse effects of the treatment.
For eyes injected with a GFP vector, green fluorescence was first evaluated in unstained sections using a Zeiss Axioplan microscope (Carl Zeiss Meditec GmbH, Oberkochen, Germany) with epifluorescence illumination (Filter Set 23 with GFP excitation at 489 nm and emission at 509 nm). Those sections with absent or weak green fluorescence were labeled with a GFP polyclonal antibody (rabbit 1:1,000). Immunohistochemical staining was performed using S-opsin polyclonal antibody (rabbit 1:5000; Chemicon, Millipore, Billerica, MA, USA; or goat 1:50; Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA), L-/M-opsin polyclonal antibody (rabbit 1:100; Chemicon; or goat 1:100; Santa Cruz), cone alpha transducin (rabbit 1:5000; Santa Cruz), human cone arrestin (rabbit 1:10 000) and canine CNGA3 (rabbit 1:5000). The latter polyclonal antibody was generated in rabbits against the C-terminal peptide of canine CNGA3 (NH2–GIPGDAAKTEIKEQ–COOH) and affinity purified. Alexa Fluor®-labeled goat anti-rabbit IgG or donkey anti-goat IgG (1:200; Molecular Probes, Inc., Eugene, OR, USA) was used as secondary antibody. DAPI stain was used to detect cell nuclei. Images were digitally captured (Spot 4.0 camera; Diagnostic Instruments, Inc., Sterling Heights, MI, USA), and imported into a graphics program (Photoshop; Adobe Systems, Inc., San Jose, CA, USA) for display. An antibody against canine CNGB3 is not available presently. Five prior attempts to produce antibodies against CNGB3 peptides (n = 4) or protein (n = 1) have not been successful, and antibodies available to CNGB3 of mouse and human are not specific in the dog.
Whole retinas were isolated from the eyecups within 1–2 min of death, flash frozen in liquid nitrogen and stored at −80°C until used. The retinal tissue was homogenized, and total RNA extracted with TRIzol Reagent (Invitrogen, Carlsbad, CA, USA) extraction. RNA concentrations were determined using a ND1000 Nanodrop spectrophotometer (NanoDrop Products, Wilmington, DE, USA). Retinal cDNA was synthesized by reverse transcription using the High Capacity cDNA Reverse Transcription kit (Applied Biosystems, Carlsbad, CA, USA) and following the manufacturer's instructions. Primers and TaqMan® MGB™ probes were designed for the hCNGB3 transgene, canine CNGA3 (cCNGA3), cCNGB3, L/M-opsin, S-opsin and rod opsin using Primer Express Software Version 2.0 [Applied Biosystems (Supplementary Material, Table S1)]. To ensure that only cDNA, and not genomic DNA, was amplified, primer pairs were designed to neighboring exon sequences. Eukaryotic 18S rRNA was used as an endogenous control (Hs99999901_s1; Applied Biosystems). Quantitative RT-PCR was conducted with TaqMan® Gene Expression Mastermix (Applied Biosystems) using an ABI 7500 Real-Time PCR System (Applied Biosystems). Each reaction was run in quadruplicate, and contained 50 ng of cDNA template along with 900 nm forward and reverse primers for each gene in a final reaction volume of 30 µl. PCR cycling parameters were 50°C for 2 min, then 95°C for 10 min, followed by 40 cycles of 95°C for 15 s and 60°C for 1 min. Relative gene expression for each gene compared with the 18S rRNA product was calculated as and compared for each gene among dog groups by one-way analysis of variance. Expression of the hCNGB3 transgene was compared with the 29 Hz flicker amplitudes by nonparametric Spearman rank correlation.
Retinas were harvested as described for qRT-PCR analysis and frozen at −80°C. Each retina was homogenized with five strokes on ice in 0.5 ml of RIPA buffer (1% Triton X-100, 1% sodium deoxycholate, 0.1% sodium dodecylsulphate, 158 mm NaCl, 10 mm Tris), containing protease inhibitor cocktail (Sigma-Aldrich Corp.). The homogenate was centrifuged for 10 min at 4°C at 14 000 rpm. Forty microgram protein was loaded onto each lane. For comparison, cultured tSA-203 cells were transfected with 1.5 µg of canine CNGA3 cDNA and cell extracts prepared as described previously (79). The primary cCNGA3 antibody was diluted at 1:500 and detected with ECL™ horseradish peroxidase-conjugated secondary anti-rabbit antibody (GE Healthcare Biosciences, Pittsburgh, PA, USA) diluted to 1:1000. For the housekeeping protein primary polyclonal beta actin antibody (rabbit; Abcam, Inc., Cambridge, MA, USA) was diluted 1:1000 and the secondary anti-rabbit antibody 1:5000. Immunoreactivity was visualized using Amersham ECL™ Western Blotting Detection Reagents (GE Healthcare).
This work was supported by the National Institutes of Health [K12-EY015398 to A.M.K. (PI: Maureen G. Maguire), R01-EY019304 to A.M.K., R01-EY013132 to G.D.A., R01-EY006855 to G.M.A., T32-EY007132 to W.W.H., P30-EY008571 to W.W.H., R01-EY011123 to W.W.H., R01-EY017549 to G.D.A., and P30-EY001583 (NEI Core Grant to the University of Pennsylvania; PI: David H. Brainard)]; the Foundation Fighting Blindness (Center grant to G.D.A.); the Macula Vision Research Foundation (to W.W.H.); the McCabe Fund (to A.M.K.); the ONCE International Prize (to G.D.A.); the Van Sloun Fund for Canine Genetic Research (to G.D.A.); Hope for Vision (to G.D.A.) and an unrestricted gift from Brittany Rockefeller and family (to G.D.A. and A.M.K.).
We thank Jeremy Nathans (Johns Hopkins University—Howard Hughes Medical Institute) for the pR2.1-LacZ plasmid; Bernd Wissinger (University Clinics Tübingen) for the hCNGB3 cDNA; W. Clay Smith (University of Florida) for the GFP antibody; Cheryl M. Craft (University of Southern California) for the hCAR antibody; and Tom Doyle and Min Ding (University of Florida) for assistance in vector production. We also thank Ann Cooper, Amanda Nickle, Gerri Antonini, Alice Eidsen, Tracy Greiner, Sanford Boye, Gui-shuang Ying, Jason Hinmon and the staff of the Retinal Disease Studies Facility at the University of Pennsylvania for technical support, and Mary Leonard for excellent illustrations. We thank Paul A. Sieving (National Eye Institute) for encouraging one of the investigators (A.M.K.) to enter the retinal research field.
Conflict of Interest statement. W.W.H. and the University of Florida have a financial interest in the use of rAAV therapies, and own equity in a company (AGTC Inc.) that may commercialize some aspects of this work. University of Pennsylvania, University of Florida and Cornell University hold a patent on the described gene therapy technology (United States Patent 20070077228, ‘Method for Treating or Retarding the Development of Blindness’). The remaining authors have declared that no conflict of interest exists.